| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab170687-100μg |
100μg |
现货  |
| |
| Ab170687-1mg |
1mg |
现货 |
| |
| Ab170687-5mg |
5mg |
现货 |
| |
| Ab170687-10mg |
10mg |
期货 |
|
| 产品名称 | Onartuzumab (anti-MET), MET 原癌基因抗体；受体酪氨酸激酶 |
|---|---|
| 别名 | 奥那妥组单抗 | 奥那珠单抗(抗 MET) |
| 英文别名 | Onartuzumab | MetMAb | Anti-HGFR / c-Met Reference Antibody (onartuzumab) | AUTS9 antibody | c met antibody | D249 antibody | Hepatocyte growth factor receptor antibody | HGF antibody | HGF receptor antibody | HGF/SF receptor antibody | HGFR antibody | ME |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | MET |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 拮抗剂 |
| 作用机制 | MET 原癌基因抗体；受体酪氨酸激酶 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 99.15 kDa |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1133766-06-9 |
| 分子类型 | 抗体 |
Onartuzumab (anti-MET) (Ab170687) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling MET (red) with Onartuzumab (anti-MET) (Ab170687). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Onartuzumab (anti-MET) (Ab170687) - SEC
The purity of Onartuzumab (anti-MET) (Ab170687) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F0911265 |
分析证书 | 24-09-26 | Ab170687 |
| ZJ24F0911266 |
分析证书 | 24-09-26 | Ab170687 |
| ZJ24F0911267 |
分析证书 | 24-09-26 | Ab170687 |
| ZJ23F1001505 |
分析证书 | 23-11-02 | Ab170687 |
| ZJ23F1001506 |
分析证书 | 23-11-02 | Ab170687 |
¥719.90
¥669.90
¥509.90
¥349.90
| 1. Morley R, Cardenas A, Hawkins P, Suzuki Y, Paton V, Phan SC, Merchant M, Hsu J, Yu W, Xia Q et al.. (2015) Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.. PLoS ONE, 10 (10): (e0139679). [PMID:26445503] |
| 2. Charakidis M, Boyer M. (2014) Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?. Transl Lung Cancer Res, 3 (6): (395-6). [PMID:25806331] |
| 3. Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. (2015) Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther, 15 (5): (487-9). [PMID:25818471] |
| 4. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer.. Proc Natl Acad Sci USA, 94 (21): (11445-50). [PMID:9326629] |
| 5. Meiners S, Brinkmann V, Naundorf H, Birchmeier W. (1998) Role of morphogenetic factors in metastasis of mammary carcinoma cells.. Oncogene, 16 (1): (9-20). [PMID:9467938] |
| 6. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433] |
| 7. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C. (2003) Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a.. Proc Natl Acad Sci USA, 100 (22): (12654-9). [PMID:14559966] |
| 8. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB et al.. (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.. J Biol Chem, 283 (5): (2675-83). [PMID:18055465] |
| 9. Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K, Hasegawa K, Kobayashi Y, Takahashi N, Takahashi K et al.. (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.. J Med Chem, 48 (5): (1359-66). [PMID:15743179] |
| 10. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al.. (2010) A structure-guided approach to creating covalent FGFR inhibitors.. Chem Biol, 17 (3): (285-95). [PMID:20338520] |
| 11. Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P et al.. (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.. J Med Chem, 55 (18): (8091-109). [PMID:22924734] |
| 12. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B et al.. (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.. Mol Cancer Ther, 10 (12): (2298-308). [PMID:21926191] |
| 13. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J et al.. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.. Proc Natl Acad Sci USA, 104 (1): (270-5). [PMID:17185414] |
| 14. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.. J Biol Chem, 282 (33): (24463-70). [PMID:17562705] |
| 15. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099] |
| 16. Oyarzabal J, Zarich N, Albarran MI, Palacios I, Urbano-Cuadrado M, Mateos G, Reymundo I, Rabal O, Salgado A, Corrionero A et al.. (2010) Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.. J Med Chem, 53 (18): (6618-28). [PMID:20722422] |
| 17. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al.. (2012) Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.. J Med Chem, 55 (3): (1082-105). [PMID:22168626] |
| 18. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R, Li Y et al.. (2011) A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.. Clin Cancer Res, 17 (22): (7127-38). [PMID:21918175] |
| 19. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.. ACS Med Chem Lett, 4 (1): (91-7). [PMID:24900568] |
| 20. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.. Mol Cancer Ther, 9 (6): (1544-53). [PMID:20484018] |
| 21. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H. (2010) E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.. Cancer Sci, 101 (1): (210-5). [PMID:19832844] |
| 22. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al.. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.. Cancer Res, 70 (4): (1524-33). [PMID:20145145] |
| 23. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP et al.. (2011) Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.. J Med Chem, 54 (6): (1871-95). [PMID:21341675] |
| 24. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, Tang CM, Huser NH, Felce JD, Froning KJ et al.. (2009) SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.. Mol Cancer Ther, 8 (12): (3181-90). [PMID:19934279] |
| 25. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R et al.. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.. Cancer Res, 63 (21): (7345-55). [PMID:14612533] |
| 26. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S et al.. (2003) Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.. Mol Cancer Ther, 2 (11): (1085-92). [PMID:14617781] |
| 27. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS. (2011) Identification and characterization of a novel integrin-linked kinase inhibitor.. J Med Chem, 54 (18): (6364-74). [PMID:21823616] |
| 28. Cho SY, Lee BH, Jung H, Yun CS, Ha JD, Kim HR, Chae CH, Lee JH, Seo HW, Oh KS. (2013) Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.. Bioorg Med Chem Lett, 23 (24): (6711-6). [PMID:24210504] |
| 29. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.. J Med Chem, 55 (2): (903-13). [PMID:22148921] |
| 30. Weinberg LR, Albom MS, Angeles TS, Husten J, Lisko JG, McHugh RJ, Milkiewicz KL, Murthy S, Ott GR, Theroff JP et al.. (2011) Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.. Bioorg Med Chem Lett, 21 (1): (164-7). [PMID:21123062] |
| 31. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S et al.. (2011) Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.. Bioorg Med Chem, 19 (21): (6274-84). [PMID:21967808] |
| 32. Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U, Blaukat A. (2015) Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.. Bioorg Med Chem Lett, 25 (7): (1597-602). [PMID:25736998] |
| 33. Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam ML, Kales AJ, Bendiksen R, Indrevoll B, Bjerke RM, Moestue SA et al.. (2015) Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met.. Nat Med, 21 (8): (955-61). [PMID:26168295] |
| 34. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al.. (2015) Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.. J Med Chem, 58 (17): (6875-98). [PMID:26222319] |
| 35. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, Chen A, Choquette D, Dussault I, Fang M et al.. (2009) Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.. Bioorg Med Chem Lett, 19 (22): (6307-12). [PMID:19819693] |
| 36. Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH et al.. (2012) Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.. Bioorg Med Chem Lett, 22 (12): (4089-93). [PMID:22595176] |
| 37. Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F et al.. (2013) EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.. Clin Cancer Res, 19 (11): (2941-51). [PMID:23553846] |
| 38. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.. Cancer Res, 71 (14): (4920-31). [PMID:21613408] |
| 39. Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J et al.. (2016) Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.. J Med Chem, 59 (10): (4948-64). [PMID:27144831] |
| 40. Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH. (2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).. Bioorg Med Chem, 15 (2): (800-14). [PMID:17098432] |
| 41. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 21 (21): (6258-63). [PMID:21958547] |
| 42. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640] |
| 43. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898] |
| 44. Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW, Manro JR et al.. (2013) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.. Invest New Drugs, 31 (4): (833-44). [PMID:23275061] |
| 45. Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, Jiao L, Cui Y, Ren Y, Fan S et al.. (2014) Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.. J Med Chem, 57 (18): (7577-89). [PMID:25148209] |
| 46. Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.. Oncotarget, 7 (4): (4093-109). [PMID:26675259] |
| 47. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al.. (2015) Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).. J Med Chem, 58 (20): (8182-99). [PMID:26431428] |
| 48. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al.. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.. J Med Chem, 61 (24): (11398-11414). [PMID:30480444] |
| 49. Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T, Wan X et al.. (2019) Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.. Eur J Med Chem, 163 (10-27). [PMID:30503936] |
| 50. Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W, Cai Z et al.. (2019) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy.. J Med Chem, 62 (14): (6665-6681). [PMID:31095385] |
| 51. Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L. (2016) Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.. Eur J Med Chem, 108 (495-504). [PMID:26717201] |
| 52. Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy ER, Sanders R, Sepulveda MA, Moores SL, Chiu ML. (2015) Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.. J Biol Chem, 290 (41): (24689-704). [PMID:26260789] |
| 53. Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun Y, Gao Y et al.. (2018) Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.. Mol Cancer Ther, 17 (4): (751-762). [PMID:29237805] |
| 54. Morgillo F, Amendola G, Della Corte CM, Giacomelli C, Botta L, Di Maro S, Messere A, Ciaramella V, Taliani S, Marinelli L et al.. (2017) Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.. J Med Chem, 60 (17): (7447-7458). [PMID:28787156] |
| 55. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong. (2013-04-23) Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.. Journal of medicinal chemistry, 56 ((9)): (3531-3545). [PMID:23600806] |
| 56. Sung Hee Hwang, Aaron T Wecksler, Guodong Zhang, Christophe Morisseau, Long V Nguyen, Samuel H Fu, Bruce D Hammock,. (2013-06-04) Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.. Bioorganic & medicinal chemistry letters, 23 ((13)): ( 3732-3737 ). [PMID:23726028] |
| 57. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern. (2014-08-05) Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.. European journal of medicinal chemistry, 85 (268-288). [PMID:25089810] |
| 58. Christine A Larsen,William H Bisson,Roderick H Dashwood. (2009-10-21) Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies.. Journal of medicinal chemistry, 52 ((21)): (6543-6545). [PMID:19839593] |
| 59. Xiaoqing Wu,Mingdong Li,Yang Qu,Wenhua Tang,Youguang Zheng,Jiqin Lian,Min Ji,Liang Xu. (2010-05-15) Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.. Bioorganic & medicinal chemistry, 18 ((11)): (3812-3822). [PMID:20466555] |
| 60. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.. Bioorg Med Chem Lett, 14 (13): (3595-3599). [PMID:15177482] [10.1016/j.bmcl.2004.03.106] |
| 61. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.. (2004) SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.. Bioorg Med Chem Lett, 14 (13): (3601-3605). [PMID:15177483] [10.1016/j.bmcl.2004.03.111] |
| 62. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA.. (2004) 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.. J Med Chem, 47 (13): (3367-3380). [PMID:15189033] [10.1021/jm031145u] |
| 63. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G.. (2006) Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.. Bioorg Med Chem Lett, 16 (2): (262-266). [PMID:16249085] [10.1016/j.bmcl.2005.10.015] |
| 64. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H.. (2007) Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.. J Med Chem, 50 (18): (4351-4373). [PMID:17696416] [10.1021/jm070034i] |
| 65. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M.. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.. J Med Chem, 50 (23): (5579-5588). [PMID:17929792] [10.1021/jm061449r] |
| 66. Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG.. (2008) Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.. J Med Chem, 51 (6): (1637-1648). [PMID:18278858] [10.1021/jm701095m] |
| 67. La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF, Harriman SP, Larrow JF, Long AM, Martin MW, Morrison MJ, Patel VF, Roveto PM, Wang L, Weiss MM, Whittington DA, Teffera Y, Zhao Z, Polverino AJ, Harmange JC.. (2008) Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.. J Med Chem, 51 (6): (1695-1705). [PMID:18311900] [10.1021/jm701129j] |
| 68. Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R.. (2008) Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.. J Med Chem, 51 (6): (1668-1680). [PMID:18324759] [10.1021/jm701098w] |
| 69. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425] [10.1073/pnas.0707498104] |
| 70. Liu L, Siegmund A, Xi N, Kaplan-Lefko P, Rex K, Chen A, Lin J, Moriguchi J, Berry L, Huang L, Teffera Y, Yang Y, Zhang Y, Bellon SF, Lee M, Shimanovich R, Bak A, Dominguez C, Norman MH, Harmange JC, Dussault I, Kim TS.. (2008) Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).. J Med Chem, 51 (13): (3688-3691). [PMID:18553959] [10.1021/jm800401t] |
| 71. Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ.. (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).. J Med Chem, 51 (24): (8012-8018). [PMID:19053756] [10.1021/jm801142b] |
| 72. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.. (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors.. J Med Chem, 51 (18): (5766-5779). [PMID:18763753] [10.1021/jm8006189] |
| 73. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG.. (2008) A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.. J Med Chem, 51 (23): (7405-7416). [PMID:18989950] [10.1021/jm800483v] |
| 74. Peach ML, Tan N, Choyke SJ, Giubellino A, Athauda G, Burke TR, Nicklaus MC, Bottaro DP.. (2009) Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.. J Med Chem, 52 (4): (943-951). [PMID:19199650] [10.1021/jm800791f] |
| 75. Jake Slavish P, Jiang Q, Cui X, Morris SW, Webb TR.. (2009) Design and synthesis of a novel tyrosine kinase inhibitor template.. Bioorg Med Chem, 17 (9): (3308-3316). [PMID:19362847] [10.1016/j.bmc.2009.03.046] |
| 76. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH.. (2009) Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.. Bioorg Med Chem Lett, 19 (16): (4720-4723). [PMID:19596575] [10.1016/j.bmcl.2009.06.066] |
| 77. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS.. (2009) Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.. J Med Chem, 52 (21): (6880-6888). [PMID:19888761] [10.1021/jm901146p] |
| 78. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424] [10.1016/j.bmcl.2009.09.094] |
| 79. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E.. (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.. J Med Chem, 53 (14): (5213-5228). [PMID:20565112] [10.1021/jm100262j] |
| 80. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM.. (2010) 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.. Bioorg Med Chem Lett, 20 (12): (3805-3808). [PMID:20466542] [10.1016/j.bmcl.2010.04.039] |
| 81. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721] [10.1016/j.bmcl.2010.11.069] |
| 82. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM.. (2011) Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.. Bioorg Med Chem, 19 (6): (1915-1923). [PMID:21353571] [10.1016/j.bmc.2011.01.067] |
| 83. Shallal HM, Russu WA.. (2011) Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.. Eur J Med Chem, 46 (6): (2043-2057). [PMID:21429632] [10.1016/j.ejmech.2011.02.057] |
| 84. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P.. (2011) Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.. Bioorg Med Chem, 19 (15): (4644-4651). [PMID:21741249] [10.1016/j.bmc.2011.06.013] |
| 85. Chavez SA, Martinko AJ, Lau C, Pham MN, Cheng K, Bevan DE, Mollnes TE, Yin H.. (2011) Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics.. J Med Chem, 54 (13): (4659-4669). [PMID:21591694] [10.1021/jm2003365] |
| 86. Kim H, Kim M, Lee J, Yu H, Hah JM.. (2011) Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.. Bioorg Med Chem, 19 (22): (6760-6767). [PMID:22014755] [10.1016/j.bmc.2011.09.042] |
| 87. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K.. (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.. J Med Chem, 54 (23): (8030-8050). [PMID:22003817] [10.1021/jm2008634] |
| 88. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.. (2012) Novel and selective spiroindoline-based inhibitors of Sky kinase.. Bioorg Med Chem Lett, 22 (1): (190-193). [PMID:22119469] [10.1016/j.bmcl.2011.11.036] |
| 89. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA.. (2012) Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.. Eur J Med Chem, 48 (143-152). [PMID:22204902] [10.1016/j.ejmech.2011.12.006] |
| 90. Ye L, Tian Y, Li Z, Jin H, Zhu Z, Wan S, Zhang J, Yu P, Zhang J, Wu S.. (2012) Design, synthesis and molecular docking studies of some novel spiro[indoline-3, 4'-piperidine]-2-ones as potential c-Met inhibitors.. Eur J Med Chem, 50 (370-375). [PMID:22381355] [10.1016/j.ejmech.2012.02.016] |
| 91. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G.. (2012) VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.. J Med Chem, 55 (2): (725-734). [PMID:22221201] [10.1021/jm201198w] |
| 92. Chen QY, Liu Y, Luesch H.. (2011) Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.. ACS Med Chem Lett, 2 (11): (861-865). [PMID:22081789] [10.1021/ml200176m] |
| 93. Norman MH, Liu L, Lee M, Xi N, Fellows I, D'Angelo ND, Dominguez C, Rex K, Bellon SF, Kim TS, Dussault I.. (2012) Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.. J Med Chem, 55 (5): (1858-1867). [PMID:22320343] [10.1021/jm201330u] |
| 94. Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S.. (2012) Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity.. J Med Chem, 55 (7): (3228-3241). [PMID:22404346] [10.1021/jm201683b] |
| 95. Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY.. (2012) Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.. J Med Chem, 55 (8): (3852-3866). [PMID:22452518] [10.1021/jm300042x] |
| 96. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.. J Med Chem, 55 (9): (4407-4424). [PMID:22533818] [10.1021/jm300309a] |
| 97. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O.. (2012) Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.. J Med Chem, 55 (11): (5467-5482). [PMID:22548342] [10.1021/jm300403a] |
| 98. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B.. (2012) Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.. Bioorg Med Chem Lett, 22 (24): (7634-7640). [PMID:23107479] [10.1016/j.bmcl.2012.10.016] |
| 99. Liang Z, Ai J, Ding X, Peng X, Zhang D, Zhang R, Wang Y, Liu F, Zheng M, Jiang H, Liu H, Geng M, Luo C.. (2013) Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.. ACS Med Chem Lett, 4 (4): (408-413). [PMID:24900685] [10.1021/ml4000047] |
| 100. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937] [10.1021/jm4002692] |
| 101. Busnena BA, Foudah AI, Melancon T, El Sayed KA.. (2013) Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer.. Bioorg Med Chem, 21 (7): (2117-2127). [PMID:23403296] [10.1016/j.bmc.2012.12.050] |
| 102. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083] |
| 103. Ye L, Ou X, Tian Y, Yu B, Luo Y, Feng B, Lin H, Zhang J, Wu S.. (2013) Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.. Eur J Med Chem, 65 (112-118). [PMID:23702473] [10.1016/j.ejmech.2013.04.004] |
| 104. Cui JJ, Shen H, Tran-Dubé M, Nambu M, McTigue M, Grodsky N, Ryan K, Yamazaki S, Aguirre S, Parker M, Li Q, Zou H, Christensen J.. (2013) Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.. J Med Chem, 56 (17): (6651-6665). [PMID:23944843] [10.1021/jm400926x] |
| 105. Li J, Wu N, Tian Y, Zhang J, Wu S.. (2013) Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors.. ACS Med Chem Lett, 4 (8): (806-810). [PMID:24900750] [10.1021/ml400203d] |
| 106. Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S.. (2013) Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.. Bioorg Med Chem, 21 (24): (7686-7698). [PMID:24216091] [10.1016/j.bmc.2013.10.028] |
| 107. Zhao H, Caflisch A.. (2014) Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.. Bioorg Med Chem Lett, 24 (6): (1523-1527). [PMID:24569110] [10.1016/j.bmcl.2014.01.083] |
| 108. Temburnikar KW, Zimmermann SC, Kim NT, Ross CR, Gelbmann C, Salomon CE, Wilson GM, Balzarini J, Seley-Radtke KL.. (2014) Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines.. Bioorg Med Chem, 22 (7): (2113-2122). [PMID:24631358] [10.1016/j.bmc.2014.02.033] |
| 109. Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.. (2014) Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.. ACS Med Chem Lett, 5 (4): (298-303). [PMID:24900830] [10.1021/ml4003309] |
| 110. Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J, Ding J, Geng M, Zhang A.. (2015) Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.. J Med Chem, 58 (1): (197-211). [PMID:24785465] [10.1021/jm5005144] |
| 111. Park BS, Al-Sanea MM, Abdelazem AZ, Park HM, Roh EJ, Park HM, Yoo KH, Sim T, Tae JS, Lee SH.. (2014) Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.. Bioorg Med Chem, 22 (15): (3871-3878). [PMID:24997577] [10.1016/j.bmc.2014.06.020] |
| 112. Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.. J Med Chem, 57 (16): (7031-7041). [PMID:25068800] [10.1021/jm500749d] |
| 113. Shi L, Wu TT, Wang Z, Xue JY, Xu YG.. (2014) Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.. Bioorg Med Chem, 22 (17): (4735-4744). [PMID:25082515] [10.1016/j.bmc.2014.07.008] |
| 114. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA.. (2015) Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.. J Med Chem, 58 (1): (443-456). [PMID:25475894] [10.1021/jm501557a] |
| 115. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.. (2015) Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.. J Med Chem, 58 (6): (2746-2763). [PMID:25699576] [10.1021/jm501929n] |
| 116. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY.. (2015) Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.. Bioorg Med Chem Lett, 25 (20): (4534-4538). [PMID:26342867] [10.1016/j.bmcl.2015.08.068] |
| 117. Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L.. (2015) Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.. Bioorg Med Chem, 23 (22): (7340-7347). [PMID:26526740] [10.1016/j.bmc.2015.10.035] |
| 118. Elkamhawy A, Farag AK, Viswanath AN, Bedair TM, Leem DG, Lee KT, Pae AN, Roh EJ.. (2015) Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.. Bioorg Med Chem Lett, 25 (22): (5147-5154). [PMID:26475520] [10.1016/j.bmcl.2015.10.003] |
| 119. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690] [10.1016/j.bmcl.2015.10.098] |
| 120. Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, Zhang S, Liu J, Liu Q.. (2015) Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.. J Med Chem, 58 (24): (9625-9638). [PMID:26630553] [10.1021/acs.jmedchem.5b01611] |
| 121. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.. (2016) Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.. Bioorg Med Chem Lett, 26 (2): (424-428). [PMID:26704265] [10.1016/j.bmcl.2015.11.099] |
| 122. Boezio AA, Copeland KW, Rex K, K Albrecht B, Bauer D, Bellon SF, Boezio C, Broome MA, Choquette D, Coxon A, Dussault I, Hirai S, Lewis R, Lin MH, Lohman J, Liu J, Peterson EA, Potashman M, Shimanovich R, Teffera Y, Whittington DA, Vaida KR, Harmange JC.. (2016) Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.. J Med Chem, 59 (6): (2328-2342). [PMID:26812066] [10.1021/acs.jmedchem.5b01716] |
| 123. Jung ME, Byun BJ, Kim HM, Lee JY, Park JH, Lee N, Son YH, Choi SU, Yang KM, Kim SJ, Lee K, Kim YC, Choi G.. (2016) Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.. Bioorg Med Chem Lett, 26 (11): (2719-2723). [PMID:27106709] [10.1016/j.bmcl.2016.03.111] |
| 124. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087] |
| 125. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079] |
| 126. Qiang H, Gu W, Huang D, Shi W, Qiu Q, Dai Y, Huang W, Qian H.. (2016) Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2.. Bioorg Med Chem, 24 (16): (3353-3358). [PMID:27068889] [10.1016/j.bmc.2016.03.061] |
| 127. Mohyeldin MM, Busnena BA, Akl MR, Dragoi AM, Cardelli JA, El Sayed KA.. (2016) Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer.. Eur J Med Chem, 118 (299-315). [PMID:27258622] [10.1016/j.ejmech.2016.04.043] |
| 128. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L.. (2017) Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).. Eur J Med Chem, 127 (72-86). [PMID:28038328] [10.1016/j.ejmech.2016.12.038] |
| 129. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076] |
| 130. Wang Y, Sun Y, Cao R, Liu D, Xie Y, Li L, Qi X, Huang N.. (2017) In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.. J Med Chem, 60 (20): (8552-8564). [PMID:28945083] [10.1021/acs.jmedchem.7b01075] |
| 131. Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ.. (2017) Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.. Eur J Med Chem, 134 (147-158). [PMID:28411455] [10.1016/j.ejmech.2017.03.085] |
| 132. Patel HM, Pawara R, Ansari A, Noolvi M, Surana S.. (2017) Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.. Bioorg Med Chem, 25 (10): (2713-2723). [PMID:28366268] [10.1016/j.bmc.2017.03.039] |
| 133. Mah S, Park JH, Jung HY, Ahn K, Choi S, Tae HS, Jung KH, Rho JK, Lee JC, Hong SS, Hong S.. (2017) Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.. J Med Chem, 60 (22): (9205-9221). [PMID:29091425] [10.1021/acs.jmedchem.7b01039] |
| 134. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031] |
| 135. Yuan H, Liu Q, Zhang L, Hu S, Chen T, Li H, Chen Y, Xu Y, Lu T.. (2018) Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.. Eur J Med Chem, 143 (491-502). [PMID:29202410] [10.1016/j.ejmech.2017.11.073] |
| 136. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI.. (2018) Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition.. Eur J Med Chem, 152 (31-52). [PMID:29684708] [10.1016/j.ejmech.2018.04.029] |
| 137. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.. (2017) Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (8): (1867-1873). [PMID:28279528] [10.1016/j.bmcl.2017.02.026] |
| 138. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020] |
| 139. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A.. (2018) Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.. J Med Chem, 61 (5): (2104-2110). [PMID:29466002] [10.1021/acs.jmedchem.7b01605] |
| 140. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L.. (2018) Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.. Eur J Med Chem, 150 (491-505). [PMID:29549836] [10.1016/j.ejmech.2018.02.080] |
| 141. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW.. (2018) Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.. Eur J Med Chem, 145 (606-621). [PMID:29348070] [10.1016/j.ejmech.2017.12.041] |
| 142. Fearon D, Westwood IM, van Montfort RLM, Bayliss R, Jones K, Bavetsias V.. (2018) Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.. Bioorg Med Chem, 26 (11): (3021-3029). [PMID:29764757] [10.1016/j.bmc.2018.04.033] |
| 143. Baladi T, Aziz J, Dufour F, Abet V, Stoven V, Radvanyi F, Poyer F, Wu TD, Guerquin-Kern JL, Bernard-Pierrot I, Garrido SM, Piguel S.. (2018) Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.. Bioorg Med Chem, 26 (20): (5510-5530). [PMID:30309671] [10.1016/j.bmc.2018.09.031] |
| 144. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031] |
| 145. Shi W, Qiang H, Huang D, Bi X, Huang W, Qian H.. (2018) Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.. Eur J Med Chem, 158 (814-831). [PMID:30248654] [10.1016/j.ejmech.2018.09.050] |
| 146. Singh PK, Chaudhari D, Jain S, Silakari O.. (2019) Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC.. Bioorg Med Chem Lett, 29 (13): (1565-1571). [PMID:31078412] [10.1016/j.bmcl.2019.05.004] |
| 147. Tang G, Liu L, Wang X, Pan Z.. (2019) Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).. Eur J Med Chem, 173 (167-183). [PMID:30999237] [10.1016/j.ejmech.2019.03.055] |
| 148. Heng H, Wang Z, Li H, Huang Y, Lan Q, Guo X, Zhang L, Zhi Y, Cai J, Qin T, Xiang L, Wang S, Chen Y, Lu T, Lu S.. (2019) Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.. Eur J Med Chem, 176 (248-267). [PMID:31103903] [10.1016/j.ejmech.2019.05.021] |
| 149. Liu S, Jiang Y, Yan R, Li Z, Wan S, Zhang T, Wu X, Hou J, Zhu Z, Tian Y, Zhang J.. (2019) Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.. Eur J Med Chem, 179 (358-375). [PMID:31260890] [10.1016/j.ejmech.2019.06.043] |
| 150. Finlay MRV, Anderton M, Bailey A, Boyd S, Brookfield J, Cairnduff C, Charles M, Cheasty A, Critchlow SE, Culshaw J, Ekwuru T, Hollingsworth I, Jones N, Leroux F, Littleson M, McCarron H, McKelvie J, Mooney L, Nissink JWM, Perkins D, Powell S, Quesada MJ, Raubo P, Sabin V, Smith J, Smith PD, Stark A, Ting A, Wang P, Wilson Z, Winter-Holt JJ, Wood JM, Wrigley GL, Yu G, Zhang P.. (2019) Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.. J Med Chem, 62 (14): (6540-6560). [PMID:31199640] [10.1021/acs.jmedchem.9b00260] |
| 151. Dokla EME, Fang CS, Abouzid KAM, Chen CS.. (2019) 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.. Eur J Med Chem, 182 (111607-111607). [PMID:31446247] [10.1016/j.ejmech.2019.111607] |
| 152. Collie GW, Koh CM, O'Neill DJ, Stubbs CJ, Khurana P, Eddershaw A, Snijder A, Mauritzson F, Barlind L, Dale IL, Shaw J, Phillips C, Hennessy EJ, Cheung T, Narvaez AJ.. (2019) Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors.. ACS Med Chem Lett, 10 (9): (1322-1327). [PMID:31531204] [10.1021/acsmedchemlett.9b00276] |
| 153. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671] [10.1021/acs.jmedchem.7b01843] |
| 154. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P.. (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.. Eur J Med Chem, 175 (309-329). [PMID:31096153] [10.1016/j.ejmech.2019.04.035] |
| 155. Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, Cirz RT, Cohen F.. (2019) Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase.. J Med Chem, 62 (16): (7489-7505). [PMID:31306011] [10.1021/acs.jmedchem.9b00625] |
| 156. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015] |
| 157. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H.. (2019) Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.. Bioorg Med Chem Lett, 29 (7): (873-877). [PMID:30755337] [10.1016/j.bmcl.2019.02.006] |
| 158. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE.. (2020) Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.. ACS Med Chem Lett, 11 (4): (558-565). [PMID:32292564] [10.1021/acsmedchemlett.0c00015] |
| 159. Nan X,Li HJ,Fang SB,Li QY,Wu YC. (2020) Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.. Eur J Med Chem, 193 (112241-112241). [PMID:32200199] [10.1016/j.ejmech.2020.112241] |
| 160. Matheson, Christopher J., Coxon, Christopher R., Bayliss, Richard, Boxall, Kathy, Carbain, Benoit, Fry, Andrew M., Hardcastle, Ian R., Harnor, Suzannah J., Mas-Droux, Corine, Newell, David R., Richards, Mark W., Sivaprakasam, Mangaleswaran, Turner, David, Griffin, Roger J., Golding, Bernard T., Cano, Celine. (2020) 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase. RSC Med Chem, 11 (6): (707-731). [PMID:33479670] [10.1039/d0md00074d] |
| 161. Zhou Y,Xu X,Wang F,He H,Gong G,Xiong L,Qi B. (2020) Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.. Eur J Med Chem, 204 (112643-112643). [PMID:32731184] [10.1016/j.ejmech.2020.112643] |
| 162. Mady MS,Mohyeldin MM,Ebrahim HY,Elsayed HE,Houssen WE,Haggag EG,Soliman RF,El Sayed KA. (2016) The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.. Bioorg Med Chem, 24 (2.0): (113-122). [PMID:26692349] [10.1016/j.bmc.2015.11.038] |
| 163. Ebrahim HY,Mohyeldin MM,Hailat MM,El Sayed KA. (2016) (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.. Bioorg Med Chem, 24 (22.0): (5748-5761). [PMID:27681240] [10.1016/j.bmc.2016.09.032] |
| 164. El-Damasy AK,Jin H,Seo SH,Bang EK,Keum G. (2020) Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.. Eur J Med Chem, 207 (112710-112710). [PMID:32961435] [10.1016/j.ejmech.2020.112710] |
| 165. Ferracini, R R, Longati, P P, Naldini, L L, Vigna, E E and Comoglio, P M PM.. (1991) Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.. The Journal of biological chemistry, (15): [PMID:1655790] |
| 166. Graziani, A A, Gramaglia, D D, Cantley, L C LC and Comoglio, P M PM.. (1991) The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase.. The Journal of biological chemistry, (25): [PMID:1718989] |
| 167. Bottaro, D P DP and 6 more authors.. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.. Science (New York, N.Y.), (15): [PMID:1846706] |
| 168. Prat, M M and 5 more authors.. (1991) The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors.. International journal of cancer, (30): [PMID:1917129] |
| 169. Park, M M and 5 more authors.. (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2819873] |
| 170. Chan, A M AM and 5 more authors.. (1987) Primary structure of the met protein tyrosine kinase domain.. Oncogene, [PMID:3325883] |
| 171. Dean, M M and 7 more authors.. (1985) The human met oncogene is related to the tyrosine kinase oncogenes.. Nature, [PMID:4069211] |
| 172. Ponzetto, C C and 8 more authors.. (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.. Cell, (22): [PMID:7513258] |
| 173. Lee, S T ST, Strunk, K M KM and Spritz, R A RA.. (1993) A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes.. Oncogene, [PMID:8247543] |
| 174. Schmidt, L L and 34 more authors.. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.. Nature genetics, [PMID:9140397] |
| 175. Boccaccio, C C and 6 more authors.. (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway.. Nature, (15): [PMID:9440692] |
| 176. Schmidt, L L and 12 more authors.. (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.. Cancer research, (15): [PMID:9563489] |
| 177. Park, W S WS and 17 more authors.. (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.. Cancer research, (15): [PMID:9927037] |
| 178. Schmidt, L L and 18 more authors.. (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas.. Oncogene, (8): [PMID:10327054] |
| 179. Olivero, M M and 9 more authors.. (1999) Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.. International journal of cancer, (27): [PMID:10417759] |
| 180. Lubensky, I A IA and 9 more authors.. (1999) Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.. The American journal of pathology, [PMID:10433944] |
| 181. Wang, J J and 8 more authors.. (1999) Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis.. Molecular and cellular biology, [PMID:10454568] |
| 182. Schiering, N N, Casale, E E, Caccia, P P, Giordano, P P and Battistini, C C.. (2000) Dimer formation through domain swapping in the crystal structure of the Grb2-SH2-Ac-pYVNV complex.. Biochemistry, (7): [PMID:11063574] |
| 183. Wang, Dakun D, Li, Zaibo Z, Messing, Edward M EM and Wu, Guan G.. (2002) Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM.. The Journal of biological chemistry, (27): [PMID:12147692] |
| 184. Giordano, Silvia S and 7 more authors.. (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met.. Nature cell biology, [PMID:12198496] |
| 185. Taher, Taher E I TE and 5 more authors.. (2002) c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:12244174] |
| 186. Palka, Helena L HL, Park, Morag M and Tonks, Nicholas K NK.. (2003) Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.. The Journal of biological chemistry, (21): [PMID:12475979] |
| 187. Wang, Dakun D, Li, Zaibo Z, Schoen, Susan R SR, Messing, Edward M EM and Wu, Guan G.. (2004) A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling.. Biochemical and biophysical research communications, (9): [PMID:14684163] |
| 188. Stamos, Jennifer J, Lazarus, Robert A RA, Yao, Xiaoyi X, Kirchhofer, Daniel D and Wiesmann, Christian C.. (2004) Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.. The EMBO journal, (16): [PMID:15167892] |
| 189. Higuchi, Toshio T and 8 more authors.. (2004) MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.. Molecular and cellular biology, [PMID:15314156] |
| 190. Wang, Dakun D, Li, Zaibo Z, Messing, Edward M EM and Wu, Guan G.. (2005) The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway.. The Journal of biological chemistry, (22): [PMID:15713673] |
| 191. Koch, Alexandra A, Mancini, Annalisa A, El Bounkari, Omar O and Tamura, Teruko T.. (2005) The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading.. Oncogene, (12): [PMID:15735664] |
| 192. Campbell, Daniel B DB and 11 more authors.. (2006) A genetic variant that disrupts MET transcription is associated with autism.. Proceedings of the National Academy of Sciences of the United States of America, (7): [PMID:17053076] |
| 193. Niemann, Hartmut H HH and 7 more authors.. (2007) Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB.. Cell, (27): [PMID:17662939] |
| 194. Jin, Pei P and 9 more authors.. (2008) Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.. Arthritis research & therapy, [PMID:18593464] |
| 195. Sangwan, Veena V and 6 more authors.. (2008) Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase.. The Journal of biological chemistry, (5): [PMID:18819921] |
| 196. Ferraris, Davide M DM, Gherardi, Ermanno E, Di, Ying Y, Heinz, Dirk W DW and Niemann, Hartmut H HH.. (2010) Ligand-mediated dimerization of the Met receptor tyrosine kinase by the bacterial invasion protein InlB.. Journal of molecular biology, (22): [PMID:19900460] |
| 197. Stella, Giulia M GM and 10 more authors.. (2011) MET mutations in cancers of unknown primary origin (CUPs).. Human mutation, [PMID:20949619] |
| 198. Kurzrock, Razelle R and 17 more authors.. (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (1): [PMID:21606412] |
| 199. Forde, Patrick M PM and Rudin, Charles M CM.. (2012) Crizotinib in the treatment of non-small-cell lung cancer.. Expert opinion on pharmacotherapy, [PMID:22594847] |
| 200. Muharram, Ghaffar G and 8 more authors.. (2014) Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.. Developmental cell, (27): [PMID:24814316] |
| 201. Mujtaba, Ghulam G and 5 more authors.. (2015) A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss.. Journal of medical genetics, [PMID:25941349] |
| 202. Hong, David S DS and 14 more authors.. (2015) A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.. Oncotarget, (30): [PMID:26155941] |
| 203. Gray, Mary J MJ and 31 more authors.. (2015) Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.. American journal of human genetics, (3): [PMID:26637977] |
| 204. Zheng, Hai H and 6 more authors.. (2016) Crystal Structure of Human Leukocyte Cell-derived Chemotaxin 2 (LECT2) Reveals a Mechanistic Basis of Functional Evolution in a Mammalian Protein with an M23 Metalloendopeptidase Fold.. The Journal of biological chemistry, (12): [PMID:27334921] |
| 205. Yang, Yifei Y and 7 more authors.. (2017) Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.. Bioorganic chemistry, [PMID:28043720] |
| 206. Tode, Naoki N and 18 more authors.. (2017) Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.. Cancer science, [PMID:28294470] |
| 207. Cavaliere, Alessandra and 7 more authors.. (2021) Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer.. European journal of nuclear medicine and molecular imaging, [PMID:32770372] |
| 208. Di Renzo, M F MF and 8 more authors.. (1991) Expression of the Met/HGF receptor in normal and neoplastic human tissues.. Oncogene, [PMID:1719465] |
| 209. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018) A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.. Eur J Med Chem, 144 (1-28). [PMID:29247857] |
首页
400-620-6333
